Empirico
Anna French, DPhil, is a Managing Partner at Qiming Venture Partners USA since 2017. In addition to this role, Anna serves as a Board Director for several companies including Renasant Bio, Umoja Biopharma, Empirico Inc., Auron Therapeutics, and Entact Bio. Past Board Directorships include Tenpoint Therapeutics Ltd, Jasper Therapeutics, and WindMIL Therapeutics, along with a Board Observer role at Talaris Therapeutics. Anna holds a PhD in Clinical and Laboratory Sciences from the University of Oxford and a BSc in Biochemistry from the University of Bristol.
This person is not in any teams
This person is not in any offices
Empirico
1 followers
Empirico is a biotechnology company focused on the discovery and development of novel medicines which are designed to mimic naturally-occurring genetic variants that confer beneficial effects on health and disease. Empirico’s two foundational and proprietary technology platforms - the Precision Insights Platform™ for genetically-validated target discovery and siRCH™ for the discovery and development of siRNA medicines - are used separately and in tandem to enable Empirico and our collaborators from the discovery and validation of novel targets to the development of clinically-viable therapeutics. Empirico’s exceptional internal capabilities, augmented by those of its partners, are driving the advancement of a growing and differentiated pipeline of wholly-owned and partnered programs. Empirico is headquartered in San Diego, CA with a major second site in Madison, WI.